CagriSema vs Tirzepatide
An approved dual incretin agonist against an investigational amylin plus GLP-1 combination; the reported magnitudes are close, the evidence maturity is not.
CagriSema
~20% in REDEFINE 1; amylin plus GLP-1 in one shot — promising, not yet approved.
Full CagriSema evidence reviewTirzepatide
Zepbound / Mounjaro
Up to ~21% mean weight loss in SURMOUNT-1 — the most effective FDA-approved weight-management drug.
Full Tirzepatide evidence reviewSide by side
| CagriSema | Tirzepatide | |
|---|---|---|
| Marketed for | Weight loss | Weight loss, type-2 diabetes |
| Evidence grade | Clinical data | FDA-approved |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | Investigational | FDA-approved |
| How it's obtained | Research-only | Rx product |
| Key human source | REDEFINE 1, NEJM 2025 | SURMOUNT-1, NEJM 2022 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Tirzepatide is approved and carries both pivotal data (SURMOUNT-1, up to roughly 20.9%) and a head-to-head win over semaglutide in SURMOUNT-5. CagriSema reported about 20% in REDEFINE 1, but it is investigational, cannot be prescribed, and has no long-term cardiovascular outcomes evidence; a notable share of participants also never reached the highest target dose, which shaped that headline figure. The two have not been compared directly, so similar-looking numbers should not be read as a tie.
CagriSema fits if
You are following amylin agonism as the next mechanism and want to see whether REDEFINE translates into an approval.
Tirzepatide fits if
You want an approved drug with the strongest head-to-head weight-loss evidence available today.